Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its earnings results on Tuesday, July, 30th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.15. The biotechnology company earned $102.22 million during the quarter, compared to analyst estimates of $89.28 million. Ironwood Pharmaceuticals's revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.22) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $374.63 million.

11 Wall Street analysts have issued 12-month price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $15.05 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

News stories about IRWD stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a news impact score of -3.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.81%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $8.88.

Ironwood Pharmaceuticals has a market capitalization of $1.39 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]